Jamie Christensen - May 23, 2022 Form 4 Insider Report for Mirati Therapeutics, Inc. (MRTX)

Role
EVP, Chief Scientific Officer
Signature
/s/ Elizabeth Gelfand, Attorney-in-Fact
Stock symbol
MRTX
Transactions as of
May 23, 2022
Transactions value $
-$39,649
Form type
4
Date filed
6/14/2022, 04:35 PM
Previous filing
Jan 18, 2022
Next filing
Sep 9, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRTX Common Stock Sale -$39.6K -624 -0.71% $63.54 86.8K May 23, 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares sold by the Company to satisfy the tax withholding obligation associated with the vesting of a portion of the restricted stock units (RSUs) granted on May 21, 2020.

Remarks:

This Form 4 is being filed late due to inadvertent administrative error.